The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study

Henrik Gregersen; Annette Juul Vangsted; Niels Abildgaard; Niels Frost Andersen; Robert Schou Pedersen; Ulf Christian Frølund; Carsten Helleberg; Bettina Broch; Per Trøllund Pedersen; Peter Gimsing; Tobias Wirenfeldt Klausen

doi:10.1002/cam4.1128

The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study

Henrik Gregersen, Annette Juul Vangsted, Niels Abildgaard, Niels Frost Andersen, Robert Schou Pedersen, Ulf Christian Frølund, Carsten Helleberg, Bettina Broch, Per Trøllund Pedersen, Peter Gimsing, Tobias Wirenfeldt Klausen

Department of Clinical Medicine

22 Citations (Scopus)

56 Downloads (Pure)

Abstract

To describe the prevalence of comorbidity and its impact on survival in newly diagnosed multiple myeloma patients compared with population controls. Cases of newly diagnosed symptomatic multiple myeloma during the 2005-2012 period were identified in the Danish National Multiple Myeloma Registry. For each myeloma patient, 10 members of the general population matched by age and sex were chosen from the national Civil Registration System. Data on comorbidity in the myeloma patients and the general population comparison cohort were collected by linkage to the Danish National Patient Registry (DNPR). Cox proportional hazards regression models were used to evaluate the prognostic significance of comorbidity. The study included 2190 cases of multiple myeloma and 21,900 population controls. The comorbidity was increased in multiple myeloma patients compared with population controls, odds ratio (OR) 1.4 (1.1-1.7). The registration of comorbidity was highly increased within the year preceding diagnosis of multiple myeloma (OR 3.0 [2.5-3.5]), which was attributable to an increased registration of various diseases, in particular, renal disease with OR 11.0 (8.1-14.9). The median follow-up time from diagnosis of multiple myeloma for patients alive was 4.3 years (interquartile range 2.4-6.3). Patients with registered comorbidity had increased mortality compared with patients without comorbidity, hazard ratio 1.6 (1.5-1.8). Multiple myeloma patients have increased comorbidity compared with the background population, in particular during the year preceding the diagnosis of myeloma.

Original language	English
Journal	Cancer Medicine
Volume	6
Issue number	7
Pages (from-to)	1807-1816
Number of pages	10
ISSN	2045-7634
DOIs	https://doi.org/10.1002/cam4.1128
Publication status	Published - Jul 2017

Keywords

Adult
Aged
Aged, 80 and over
Case-Control Studies
Comorbidity
Denmark/epidemiology
Female
Hematopoietic Stem Cell Transplantation
Humans
Male
Melphalan/administration & dosage
Middle Aged
Mortality
Multiple Myeloma/diagnosis
Odds Ratio
Population Surveillance
Prognosis
Proportional Hazards Models
Registries
Risk Factors
Transplantation Conditioning
Young Adult

Access to Document

10.1002/cam4.1128Licence: CC BY

The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based studyFinal published version, 185 KBLicence: CC BY

Cite this

@article{41030e55751c460a963272faa1b9f368,

title = "The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study",

abstract = "To describe the prevalence of comorbidity and its impact on survival in newly diagnosed multiple myeloma patients compared with population controls. Cases of newly diagnosed symptomatic multiple myeloma during the 2005-2012 period were identified in the Danish National Multiple Myeloma Registry. For each myeloma patient, 10 members of the general population matched by age and sex were chosen from the national Civil Registration System. Data on comorbidity in the myeloma patients and the general population comparison cohort were collected by linkage to the Danish National Patient Registry (DNPR). Cox proportional hazards regression models were used to evaluate the prognostic significance of comorbidity. The study included 2190 cases of multiple myeloma and 21,900 population controls. The comorbidity was increased in multiple myeloma patients compared with population controls, odds ratio (OR) 1.4 (1.1-1.7). The registration of comorbidity was highly increased within the year preceding diagnosis of multiple myeloma (OR 3.0 [2.5-3.5]), which was attributable to an increased registration of various diseases, in particular, renal disease with OR 11.0 (8.1-14.9). The median follow-up time from diagnosis of multiple myeloma for patients alive was 4.3 years (interquartile range 2.4-6.3). Patients with registered comorbidity had increased mortality compared with patients without comorbidity, hazard ratio 1.6 (1.5-1.8). Multiple myeloma patients have increased comorbidity compared with the background population, in particular during the year preceding the diagnosis of myeloma.",

keywords = "Adult, Aged, Aged, 80 and over, Case-Control Studies, Comorbidity, Denmark/epidemiology, Female, Hematopoietic Stem Cell Transplantation, Humans, Male, Melphalan/administration & dosage, Middle Aged, Mortality, Multiple Myeloma/diagnosis, Odds Ratio, Population Surveillance, Prognosis, Proportional Hazards Models, Registries, Risk Factors, Transplantation Conditioning, Young Adult",

author = "Henrik Gregersen and Vangsted, {Annette Juul} and Niels Abildgaard and Andersen, {Niels Frost} and Pedersen, {Robert Schou} and Fr{\o}lund, {Ulf Christian} and Carsten Helleberg and Bettina Broch and Pedersen, {Per Tr{\o}llund} and Peter Gimsing and Klausen, {Tobias Wirenfeldt}",

note = "{\textcopyright} 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.",

year = "2017",

month = jul,

doi = "10.1002/cam4.1128",

language = "English",

volume = "6",

pages = "1807--1816",

journal = "Cancer Medicine",

issn = "2045-7634",

publisher = "JohnWiley & Sons Ltd",

number = "7",

}

TY - JOUR

T1 - The impact of comorbidity on mortality in multiple myeloma

T2 - a Danish nationwide population-based study

AU - Gregersen, Henrik

AU - Vangsted, Annette Juul

AU - Abildgaard, Niels

AU - Andersen, Niels Frost

AU - Pedersen, Robert Schou

AU - Frølund, Ulf Christian

AU - Helleberg, Carsten

AU - Broch, Bettina

AU - Pedersen, Per Trøllund

AU - Gimsing, Peter

AU - Klausen, Tobias Wirenfeldt

PY - 2017/7

Y1 - 2017/7

N2 - To describe the prevalence of comorbidity and its impact on survival in newly diagnosed multiple myeloma patients compared with population controls. Cases of newly diagnosed symptomatic multiple myeloma during the 2005-2012 period were identified in the Danish National Multiple Myeloma Registry. For each myeloma patient, 10 members of the general population matched by age and sex were chosen from the national Civil Registration System. Data on comorbidity in the myeloma patients and the general population comparison cohort were collected by linkage to the Danish National Patient Registry (DNPR). Cox proportional hazards regression models were used to evaluate the prognostic significance of comorbidity. The study included 2190 cases of multiple myeloma and 21,900 population controls. The comorbidity was increased in multiple myeloma patients compared with population controls, odds ratio (OR) 1.4 (1.1-1.7). The registration of comorbidity was highly increased within the year preceding diagnosis of multiple myeloma (OR 3.0 [2.5-3.5]), which was attributable to an increased registration of various diseases, in particular, renal disease with OR 11.0 (8.1-14.9). The median follow-up time from diagnosis of multiple myeloma for patients alive was 4.3 years (interquartile range 2.4-6.3). Patients with registered comorbidity had increased mortality compared with patients without comorbidity, hazard ratio 1.6 (1.5-1.8). Multiple myeloma patients have increased comorbidity compared with the background population, in particular during the year preceding the diagnosis of myeloma.

AB - To describe the prevalence of comorbidity and its impact on survival in newly diagnosed multiple myeloma patients compared with population controls. Cases of newly diagnosed symptomatic multiple myeloma during the 2005-2012 period were identified in the Danish National Multiple Myeloma Registry. For each myeloma patient, 10 members of the general population matched by age and sex were chosen from the national Civil Registration System. Data on comorbidity in the myeloma patients and the general population comparison cohort were collected by linkage to the Danish National Patient Registry (DNPR). Cox proportional hazards regression models were used to evaluate the prognostic significance of comorbidity. The study included 2190 cases of multiple myeloma and 21,900 population controls. The comorbidity was increased in multiple myeloma patients compared with population controls, odds ratio (OR) 1.4 (1.1-1.7). The registration of comorbidity was highly increased within the year preceding diagnosis of multiple myeloma (OR 3.0 [2.5-3.5]), which was attributable to an increased registration of various diseases, in particular, renal disease with OR 11.0 (8.1-14.9). The median follow-up time from diagnosis of multiple myeloma for patients alive was 4.3 years (interquartile range 2.4-6.3). Patients with registered comorbidity had increased mortality compared with patients without comorbidity, hazard ratio 1.6 (1.5-1.8). Multiple myeloma patients have increased comorbidity compared with the background population, in particular during the year preceding the diagnosis of myeloma.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Case-Control Studies

KW - Comorbidity

KW - Denmark/epidemiology

KW - Female

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Male

KW - Melphalan/administration & dosage

KW - Middle Aged

KW - Mortality

KW - Multiple Myeloma/diagnosis

KW - Odds Ratio

KW - Population Surveillance

KW - Prognosis

KW - Proportional Hazards Models

KW - Registries

KW - Risk Factors

KW - Transplantation Conditioning

KW - Young Adult

U2 - 10.1002/cam4.1128

DO - 10.1002/cam4.1128

M3 - Journal article

C2 - 28639741

SN - 2045-7634

VL - 6

SP - 1807

EP - 1816

JO - Cancer Medicine

JF - Cancer Medicine

IS - 7

ER -

The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study

Abstract

Keywords

Access to Document

Fingerprint

Cite this